TITLE

Maxamine/IL-2 Combination Promising As AML Treatment

PUB. DATE
October 1999
SOURCE
Worldwide Biotech;Oct99, Vol. 11 Issue 10, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Highlights the Maxim Pharmaceuticals' report on the first clinical data demonstrating that combination treatment with Maxamine (histamine) and interleukin-2 increased a key indicator of white blood cell function in patients with acute myelogenous leukemia (AML). Objective of Maxamine Therapy; Information on CD3 zeta molecule research; Overview of Maxim Pharmaceuticals.
ACCESSION #
2330926

 

Related Articles

  • Remission; Possible.  // Pharmaceutical Executive;Apr98, Vol. 18 Issue 4, p112 

    Reports that Maxim Pharmaceuticals has initiated a Phase II clinical trial of Maxamine Therapy, a treatment for acute myelogenous leukemia (AML). Maxim's collaboration agreement with Chiron Corp. to use Chiron's Proleukin in combination with Maxamine in the trial; Effort to prolong disease-free...

  • Acute Leukemia.  // Current Medical Literature: Leukemia & Lymphoma;2013, Vol. 21 Issue 4, p119 

    A review of the article "Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study," by A. Shah and colleagues, which appeared in the periodical "British Journal of Haematology" in the 2013 issue, is presented.

  • TREATMENT GOAL FOR ACUTE MYELOID LEUKEMIA.  // Clinical Advisor;Sep2010, Vol. 13 Issue 9, p61 

    The article presents an answer to a question related to the treatment goal of a man with acute myeloid leukemia (AML) who also has other health problems.

  • Hematology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS31 

    Presents an abstract of the research manuscript `High dose Ara-C versus intermediate dose Ara-C as consolidation in adult AML: 5 year follow-up,' by M.K. Gandhi, M. Crump and A. Keating. Acute myelocytic leukemia (AML).

  • Differentiation therapy in acute myelogenous leukemia (non-APL). Waxman, S // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p491 

    Successful treatment of acute promyelocytic leukemia (APL) has identified several novel approaches to induce leukemic cell differentiation and selective apoptosis by overcoming the site-specific transcriptional repression by dominant fusion leukemogenic proteins characteristic of APL and other...

  • Treatment of relapsed and refractory acute myelogenous leukemia. Estey, E H // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p476 

    Evidence suggests that the salvage therapy utilized for relapsed and refractory acute myelogenous leukemia (AML) should differ based on the duration of a patient's complete remission (CR), the principal predictor of outcome. While standard regimens have produced higher CR rates than...

  • Antidepressant as Cancer Treatment….  // BioWorld Today;3/19/2012, Vol. 23 Issue 43, Special section p1 

    The article reports that Vesanoid, combined with an antidepressant, can treat some other types of acute myeloid leukemia (AML), according to the British Institute for Cancer Research.

  • Removal of Abnormal Clone of Leukaemic Cells by Splenectomy. Gomez, G.; Hossfeld, D.K.; Sokal, J.E. // British Medical Journal;5/24/1975, Vol. 2 Issue 5968, p421 

    Reports the removal of chronic myelocytic leukemia (CML) by splenectomy. Characteristics of CML; Abnormality in Philadelphia chromosomes; Recurrence of karyotypic abnormalities found in splenic specimen; Application of chemotherapy and immunotherapy.

  • Marlene's story. Paulson, Marlene // Alive;Jul2013, Issue 369, p3 

    A personal narrative is presented which explores the author's experience of being treated for acute myelogenous leukemia at Dr. Castillo's Clinic in Tijuana, New Mexico.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics